The recurrence rate of prostate cancer following primary definitive treatment varies dramatically depending on the initial stage of the disease, the patient's Gleason score, pre-treatment PSA levels, and the specific therapeutic modality utilized. Generally, studies indicate that biochemical recurrence—indicated by a rising PSA level—can occur in roughly 20 to 40 percent of patients over a ten-year horizon following localized treatments such as radical prostatectomy or radiation therapy. Early-stage, low-risk tumors boast exceptionally high long-term cure rates with low recurrence probabilities, whereas high-risk or locally advanced cancers carry a significantly higher likelihood of returning, necessitating ongoing post-treatment medical surveillance.